FDA approves Orlynvah (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections – Iterum Therapeutics
Iterum Therapeutics plc announced that the FDA has approved Iterum’s new drug application for Orlynvah (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs)… read more.
